These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27396951)

  • 21. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
    Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
    Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
    Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
    Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
    Shen CC; Cheng WY; Lee CH; Dai XJ; Chiao MT; Liang YJ; Hsieh WY; Mao TF; Lin GS; Chen SR; Liu BS; Chen JP
    BMC Cancer; 2020 Jul; 20(1):709. PubMed ID: 32727419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
    Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
    Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
    Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
    Sippl C; Ketter R; Braun L; Teping F; Schoeneberger L; Kim YJ; List M; Nakhoda A; Wemmert S; Oertel J; Urbschat S
    Acta Neurochir (Wien); 2019 Nov; 161(11):2299-2309. PubMed ID: 31478117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
    Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M;
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.
    Otani Y; Ichikawa T; Kurozumi K; Inoue S; Ishida J; Oka T; Shimizu T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Michiue H; Date I
    Oncogene; 2018 Feb; 37(6):777-786. PubMed ID: 29059154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
    Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
    AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
    Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
    J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
    Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
    J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients.
    Chen W; Yu Q; Chen B; Lu X; Li Q
    Oncotarget; 2016 Aug; 7(33):53392-53413. PubMed ID: 27438144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.
    Zhang W; Zhang J; Yan W; You G; Bao Z; Li S; Kang C; Jiang C; You Y; Zhang Y; Chen CC; Song SW; Jiang T
    Cancer; 2013 Feb; 119(4):814-24. PubMed ID: 22990979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastoma.
    Fu M; Hussain A; Dong Y; Fei Y
    J Clin Neurosci; 2021 Apr; 86():110-115. PubMed ID: 33775313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
    Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
    J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
    Urup T; Dahlrot RH; Grunnet K; Christensen IJ; Michaelsen SR; Toft A; Larsen VA; Broholm H; Kosteljanetz M; Hansen S; Poulsen HS; Lassen U
    Acta Oncol; 2016; 55(4):418-22. PubMed ID: 26828563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.